Ideaya Biosciences Inc. (IDYA) NASDAQ

$10.74 0.54 (5.29%)

Market Cap: $422.14M

As of 08/16/22 04:00 PM EDT. Market closed.

(IDYA)

Ideaya Biosciences Inc. (IDYA) NASDAQ

$10.74 0.54 (5.29%)

Market Cap: $422.14M

As of 08/16/22 04:00 PM EDT. Market closed.

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from ... read more

IDEAYA Biosciences Inc. is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality - which represents an emerging class of precision medicine targets. read less

COMPANY PROFILE
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO
Yujiro Hata
Full Time Employees
62
URL
Address
7000 Shoreline Ct Ste 350, California, South San Francisco, 94080-7604.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
CEO
Yujiro Hata
Full Time Employees
62
Address
7000 Shoreline Ct Ste 350, California, South San Francisco, 94080-7604.
PRICE CHART
1w
1m
3m
6m
YTD
1y
5y
MAX
From: To:
NEWS
KEY STATS
Open
$0
Previous Close
$10.20
Days Range
$10 - $10.83
52 week range
$8.14 - $28
Volume
10,635
Avg. Volume (30 days)
369,683
Market Cap
$422.14M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
39,305,802
Open
$0
Previous Close
$10.20
Days Range
$10 - $10.83
52 week range
$8.14 - $28
Volume
10,635
Avg. Volume (30 days)
369,683
Market Cap
$422.14M
Dividend Yield
0.00%
P/E
-
Shares Outstanding
39,305,802

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

Open in: SeekingAlpha Yahoo Finance Fidelity MorningStar

INSIDER TRANSACTIONS FOR IDEAYA BIOSCIENCES INC
Owner Relationship Date Transaction Cost # Shares Value($) Total Shares Form 4
Stone Paul A. SVP, Chief Financial Officer May 28, 2021 Option Exercise $11.36 859 9,762 13,803 Apr 14, 2022, 04:10 PM
Dillon Michael P. SVP, Chief Scientific Officer Oct 04, 2021 Option Exercise $11.08 1,500 16,620 80,289 Oct 07, 2021, 04:11 PM
Dillon Michael P. SVP, Chief Scientific Officer Oct 04, 2021 Sale $26.36 1,500 39,545 79,789 Oct 07, 2021, 04:11 PM
Dillon Michael P. SVP, Chief Scientific Officer Sep 07, 2021 Option Exercise $4.31 116 500 78,905 Sep 09, 2021, 07:24 PM
Dillon Michael P. SVP, Chief Scientific Officer Sep 08, 2021 Option Exercise $6.87 11,384 78,264 90,173 Sep 09, 2021, 07:24 PM
Dillon Michael P. SVP, Chief Scientific Officer Sep 07, 2021 Sale $27.46 116 3,185 78,789 Sep 09, 2021, 07:24 PM
Dillon Michael P. SVP, Chief Scientific Officer Sep 08, 2021 Sale $27.42 11,384 312,093 78,989 Sep 09, 2021, 07:24 PM
Stone Paul A. SVP, Chief Financial Officer Sep 07, 2021 Sale $27.42 2,500 68,542 12,944 Sep 09, 2021, 05:41 PM
Dillon Michael P. SVP, Chief Scientific Officer Sep 02, 2021 Sale $25.09 10,000 250,943 78,789 Sep 07, 2021, 06:48 PM
Dillon Michael P. SVP, Chief Scientific Officer Aug 09, 2021 Option Exercise $4.31 1,500 6,465 100,289 Aug 11, 2021, 05:19 PM
Dillon Michael P. SVP, Chief Scientific Officer Aug 09, 2021 Sale $22.98 11,500 264,269 89,189 Aug 11, 2021, 05:19 PM
Dillon Michael P. SVP, Chief Scientific Officer Jul 27, 2021 Option Exercise $5.62 10,000 56,150 108,789 Jul 29, 2021, 05:18 PM
Dillon Michael P. SVP, Chief Scientific Officer Jul 27, 2021 Sale $25.15 10,000 251,460 98,789 Jul 29, 2021, 05:18 PM
Throne Jason SVP, General Counsel Jul 27, 2021 Option Exercise $13.34 10,000 133,400 10,000 Jul 29, 2021, 05:17 PM
Throne Jason SVP, General Counsel Jul 27, 2021 Sale $25.17 10,000 251,683 0 Jul 29, 2021, 05:17 PM
Dillon Michael P. SVP, Chief Scientific Officer Jul 06, 2021 Option Exercise $6.92 1,500 10,380 100,289 Jul 08, 2021, 07:01 PM
Dillon Michael P. SVP, Chief Scientific Officer Jul 06, 2021 Sale $22.24 1,500 33,358 98,889 Jul 08, 2021, 07:01 PM
Throne Jason SVP, General Counsel Jul 06, 2021 Option Exercise $8.52 10,000 85,229 10,000 Jul 08, 2021, 07:00 PM
Throne Jason SVP, General Counsel Jul 06, 2021 Sale $22.24 10,000 222,408 3,532 Jul 08, 2021, 07:00 PM
Dillon Michael P. SVP, Chief Scientific Officer Feb 09, 2021 Option Exercise $6.92 5,000 34,600 103,789 Feb 10, 2021, 07:31 PM
Dillon Michael P. SVP, Chief Scientific Officer Feb 09, 2021 Sale $20.74 5,000 103,696 98,789 Feb 10, 2021, 07:31 PM
Lackner Mark SVP, Head of Biology Feb 10, 2021 Option Exercise $6.98 596 4,160 596 Feb 10, 2021, 06:53 PM
Lackner Mark SVP, Head of Biology Feb 09, 2021 Option Exercise $6.98 1,104 7,706 1,104 Feb 10, 2021, 06:53 PM
Lackner Mark SVP, Head of Biology Feb 08, 2021 Option Exercise $6.98 300 2,094 300 Feb 10, 2021, 06:53 PM
Lackner Mark SVP, Head of Biology Feb 10, 2021 Sale $21.00 596 12,516 0 Feb 10, 2021, 06:53 PM
Lackner Mark SVP, Head of Biology Feb 09, 2021 Sale $21.05 1,104 23,234 0 Feb 10, 2021, 06:53 PM
Lackner Mark SVP, Head of Biology Feb 08, 2021 Sale $21.01 300 6,302 200 Feb 10, 2021, 06:53 PM
BVF PARTNERS L P/IL See Explanation of Responses Feb 02, 2021 Sale $18.00 46,409 835,362 1,642,186 Feb 04, 2021, 05:15 PM
Lackner Mark SVP, Head of Biology Jan 26, 2021 Option Exercise $6.39 1,500 9,580 2,501 Jan 28, 2021, 04:59 PM
Lackner Mark SVP, Head of Biology Jan 26, 2021 Sale $18.46 2,501 46,158 800 Jan 28, 2021, 04:59 PM
Hata Yujiro S President and CEO Dec 22, 2020 Option Exercise $4.31 8,000 34,480 666,286 Dec 23, 2020, 04:06 PM
Dillon Michael P. SVP, Chief Scientific Officer Dec 18, 2020 Option Exercise $4.31 7,750 33,402 98,789 Dec 22, 2020, 05:35 PM
Throne Jason SVP, General Counsel Dec 04, 2020 Sale $15.37 1,979 30,410 1,579 Dec 08, 2020, 04:03 PM
5AM Ventures IV, L.P. 10% Owner Nov 11, 2020 Sale $13.66 800,000 10,928,000 2,187,428 Nov 13, 2020, 08:53 PM
BVF PARTNERS L P/IL 10% Owner Jun 30, 2020 Buy $13.32 2,531 33,704 1,667,420 Jul 02, 2020, 06:51 PM
BVF PARTNERS L P/IL 10% Owner Jun 22, 2020 Buy $13.93 19,732 274,960 1,665,899 Jun 22, 2020, 07:52 PM
BVF PARTNERS L P/IL 10% Owner Jun 19, 2020 Buy $14.39 98,264 1,413,970 1,655,375 Jun 22, 2020, 07:52 PM
Stone Paul A. Chief Financial Officer Jun 17, 2020 Option Exercise $4.62 3,100 14,322 18,100 Jun 19, 2020, 07:46 PM
Stone Paul A. Chief Financial Officer Jun 17, 2020 Sale $17.97 3,100 55,717 15,600 Jun 19, 2020, 07:46 PM
Lackner Mark SVP, Head of Biology Jun 17, 2020 Option Exercise $4.62 373 1,723 373 Jun 18, 2020, 06:03 PM
Lackner Mark SVP, Head of Biology Jun 16, 2020 Option Exercise $5.62 6,750 37,942 6,750 Jun 18, 2020, 06:03 PM
Lackner Mark SVP, Head of Biology Jun 17, 2020 Sale $19.91 373 7,428 0 Jun 18, 2020, 06:03 PM
Lackner Mark SVP, Head of Biology Jun 16, 2020 Sale $14.93 6,750 100,761 0 Jun 18, 2020, 06:03 PM
Throne Jason VP, General Counsel Jun 04, 2020 Sale $8.66 2,205 19,087 0 Jun 08, 2020, 04:51 PM
Lackner Mark SVP, Head of Biology Jun 02, 2020 Sale $9.21 845 7,779 437 Jun 04, 2020, 05:40 PM
Hata Yujiro S President and CEO Apr 15, 2020 Option Exercise $4.31 47,564 205,001 658,286 Apr 16, 2020, 05:33 PM
Stone Paul A. Chief Financial Officer Mar 30, 2020 Option Exercise $4.62 5,000 23,100 15,000 Apr 01, 2020, 04:06 PM
Hata Yujiro S President and CEO Jul 30, 2019 Option Exercise $4.31 15,000 64,650 610,722 Aug 01, 2019, 12:20 PM
Hager Jeffrey SVP, Chief Technology Officer Jul 26, 2019 Option Exercise $4.31 5,197 22,399 127,853 Jul 30, 2019, 07:20 PM
Stone Paul A. SVP, General Counsel Jul 26, 2019 Option Exercise $4.62 10,000 46,200 10,000 Jul 29, 2019, 04:27 PM
Hager Jeffrey SVP, Chief Technology Officer Jul 10, 2019 Option Exercise $4.31 7,145 30,795 122,656 Jul 26, 2019, 12:50 PM
Hager Jeffrey SVP, Chief Technology Officer Jun 19, 2019 Option Exercise $4.31 8,628 37,187 115,511 Jul 26, 2019, 12:50 PM
Alexandria Venture Investments, LLC 10% Owner May 28, 2019 Buy $10.00 50,000 500,000 432,384 May 30, 2019, 06:12 PM
DIEKMAN JOHN D Director May 28, 2019 Buy $10.00 250,000 2,500,000 2,844,545 May 28, 2019, 09:14 PM
Stone Paul A. SVP, General Counsel May 28, 2019 Buy $10.00 250,000 2,500,000 2,844,545 May 28, 2019, 09:08 PM
5AM Ventures IV, L.P. 10% Owner May 28, 2019 Buy $10.00 750,000 7,500,000 2,844,545 May 28, 2019, 08:40 PM
SHANNON TIMOTHY M Director May 28, 2019 Buy $10.00 400,000 4,000,000 2,660,713 May 28, 2019, 04:56 PM
CANAAN X L.P. 10% Owner May 28, 2019 Buy $10.00 400,000 4,000,000 2,660,713 May 28, 2019, 04:55 PM
Load More Insider Transactions
Buy Sale Option Exercise
Owner Relationship Date Value($)
Stone Paul A. SVP, Chief Financial Officer 05/28/2021 9,762
Dillon Michael P. SVP, Chief Scientific Officer 10/04/2021 16,620
Dillon Michael P. SVP, Chief Scientific Officer 10/04/2021 39,545
Dillon Michael P. SVP, Chief Scientific Officer 09/07/2021 500
Dillon Michael P. SVP, Chief Scientific Officer 09/08/2021 78,264
Dillon Michael P. SVP, Chief Scientific Officer 09/07/2021 3,185
Dillon Michael P. SVP, Chief Scientific Officer 09/08/2021 312,093
Stone Paul A. SVP, Chief Financial Officer 09/07/2021 68,542
Dillon Michael P. SVP, Chief Scientific Officer 09/02/2021 250,943
Dillon Michael P. SVP, Chief Scientific Officer 08/09/2021 6,465
Dillon Michael P. SVP, Chief Scientific Officer 08/09/2021 264,269
Dillon Michael P. SVP, Chief Scientific Officer 07/27/2021 56,150
Dillon Michael P. SVP, Chief Scientific Officer 07/27/2021 251,460
Throne Jason SVP, General Counsel 07/27/2021 133,400
Throne Jason SVP, General Counsel 07/27/2021 251,683
Dillon Michael P. SVP, Chief Scientific Officer 07/06/2021 10,380
Dillon Michael P. SVP, Chief Scientific Officer 07/06/2021 33,358
Throne Jason SVP, General Counsel 07/06/2021 85,229
Throne Jason SVP, General Counsel 07/06/2021 222,408
Dillon Michael P. SVP, Chief Scientific Officer 02/09/2021 34,600
Dillon Michael P. SVP, Chief Scientific Officer 02/09/2021 103,696
Lackner Mark SVP, Head of Biology 02/10/2021 4,160
Lackner Mark SVP, Head of Biology 02/09/2021 7,706
Lackner Mark SVP, Head of Biology 02/08/2021 2,094
Lackner Mark SVP, Head of Biology 02/10/2021 12,516
Lackner Mark SVP, Head of Biology 02/09/2021 23,234
Lackner Mark SVP, Head of Biology 02/08/2021 6,302
BVF PARTNERS L P/IL See Explanation of Responses 02/02/2021 835,362
Lackner Mark SVP, Head of Biology 01/26/2021 9,580
Lackner Mark SVP, Head of Biology 01/26/2021 46,158
Hata Yujiro S President and CEO 12/22/2020 34,480
Dillon Michael P. SVP, Chief Scientific Officer 12/18/2020 33,402
Throne Jason SVP, General Counsel 12/04/2020 30,410
5AM Ventures IV, L.P. 10% Owner 11/11/2020 10,928,000
BVF PARTNERS L P/IL 10% Owner 06/30/2020 33,704
BVF PARTNERS L P/IL 10% Owner 06/22/2020 274,960
BVF PARTNERS L P/IL 10% Owner 06/19/2020 1,413,970
Stone Paul A. Chief Financial Officer 06/17/2020 14,322
Stone Paul A. Chief Financial Officer 06/17/2020 55,717
Lackner Mark SVP, Head of Biology 06/17/2020 1,723
Lackner Mark SVP, Head of Biology 06/16/2020 37,942
Lackner Mark SVP, Head of Biology 06/17/2020 7,428
Lackner Mark SVP, Head of Biology 06/16/2020 100,761
Throne Jason VP, General Counsel 06/04/2020 19,087
Lackner Mark SVP, Head of Biology 06/02/2020 7,779
Hata Yujiro S President and CEO 04/15/2020 205,001
Stone Paul A. Chief Financial Officer 03/30/2020 23,100
Hata Yujiro S President and CEO 07/30/2019 64,650
Hager Jeffrey SVP, Chief Technology Officer 07/26/2019 22,399
Stone Paul A. SVP, General Counsel 07/26/2019 46,200
Hager Jeffrey SVP, Chief Technology Officer 07/10/2019 30,795
Hager Jeffrey SVP, Chief Technology Officer 06/19/2019 37,187
Alexandria Venture Investments, LLC 10% Owner 05/28/2019 500,000
DIEKMAN JOHN D Director 05/28/2019 2,500,000
Stone Paul A. SVP, General Counsel 05/28/2019 2,500,000
5AM Ventures IV, L.P. 10% Owner 05/28/2019 7,500,000
SHANNON TIMOTHY M Director 05/28/2019 4,000,000
CANAAN X L.P. 10% Owner 05/28/2019 4,000,000
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING
STOCK BUYBACKS
Period of Report
Previous Period
% Change in Shares
10-K/10-Q Filings
Quarter
06/30/2022
12/31/2021
9.57%
2Q
06/30/2022
06/30/2021
19.51%
4Q
06/30/2022
03/31/2021
21.62%
5Q

Period of Report: 06/30/2022

10-K/10-Q Filings: View

Previous Period
% Change in Shares
Quarter
12/31/2021
9.57%
2Q
06/30/2021
19.51%
4Q
03/31/2021
21.62%
5Q